• 100+

    The UK’s most active investor in UK university spin-outs

  • £250M

    Over £250m raised; invested into over 100 companies

  • 16 wins

    Award winning manager with track record of delivering returns

  • £1.1Bn

    Part of FTSE 250 sector specialist group with £1.1bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.
Covid-19 Update: We continue to operate as usual, supporting the best of our technology companies. We accept applications by email and are having video updates with investors and advisers. Further details here.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Steve Churchhouse
Cassie Doherty
Susie Harris
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Bibliu

Bibliu (formerly Bibliotech) provides broad textbook content through an online subscription offering that offers students enhanced search, annotation and other services. This addresses the problem of the high cost of textbooks and the limited availability and restricted use of textbooks from libraries. The Bibliu platform also allows universities, departments, libraries and publishers to monitor u

VocalIQ

VocalIQ exploited technology developed by the Spoken Dialogue Systems Group at University of Cambridge. The technology has wide applicability for automated spoken language interfaces, including smartphones, smart speakers, robots, cars, call-centres, and games. In September 2015 VocalIQ was acquired by a leading US consumer electronics company.

Petmedix

PetMedix is utilising tried and tested antibody technology to develop treatments for diseases in companion animals. Monoclonal antibodies are now a hugely important human drug class but are in their infancy in the treatment of animals. PetMedix will take tried and tested techniques and apply them to the treatment of dogs and cats.

View Portfolio